Suppr超能文献

[多巴胺能治疗对帕金森病运动并发症影响的系统评价]

[Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].

作者信息

Zhou Ming-Zhu, Liu Zhen-Guo, Chen Wei, Lu Li-Xia, Wu Jia-Ying, Qi Chen

机构信息

Department of Neurology, Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2009 Feb 24;89(7):438-44.

Abstract

OBJECTIVE

To investigate the impact of dopaminergic therapy on the onset of motor complications in Parkinson's disease (PD).

METHODS

Two clinical questions were identified. (1) Whether levodopa (LD) dose, LD treatment duration, the time from disease onset to initiation of LD can predict the onset of motor complications in PD? and (2) whether dopamine agonists (DA) used in de novo patients can delay the onset of motor complications? Literatures on observation studies of factors associated with motor complications and randomized controlled trials (RCTs) of DA compared to LD in treatment of de novo patients published before May 2008 were retrieved from Pubmed, EMbase, and Cochrane Database. Methodology quality was critically assessed.

RESULTS

12 articles on the first question were selected, including one RCT, five cohort studies, six case-control studies. Six RCTs on the second question were selected. Because of clinical heterogeneity among the researches thus retrieved, meta-analysis was not conducted, and qualitative analysis showed that initial LD dose, LD dose per kilogram body weight, accumulated LD dose, and accumulated LD equivalent dose might be independent factors associated with motor complications. The time from disease onset to initiation of LD was not correlated with motor complications. DA as initial treatment was associated with later occurrence of dyskinesias (CALM-PD: HR = 0.37, 95% CI: 0.25 - 0.56, P < 0.001; PELMOPET: HR = 0.48, 95% CI = 0.29 - 0.80, P < 0.001; Ropinirole 056: HR = 0.4, 95% CI: 0.2 - 0.8, P = 0.007; REAL-PET: HR = 8.28, 95% CI: 2.46 - 27.93, P < 0.001). The relationship between LD treatment duration and motor complications could not be concluded from present evidence.

CONCLUSION

Initial LD dose, LD dose per kilogram body weight, accumulated LD dose, and accumulated LD equivalent dose may be independent factors associated with motor complications. The time from disease onset to initiation of LD was not correlated with motor complications.

摘要

目的

探讨多巴胺能治疗对帕金森病(PD)运动并发症发生的影响。

方法

确定了两个临床问题。(1)左旋多巴(LD)剂量、LD治疗时长、从疾病发作到开始使用LD的时间能否预测PD运动并发症的发生?以及(2)初治患者使用多巴胺激动剂(DA)能否延迟运动并发症的发生?从PubMed、EMbase和Cochrane数据库中检索了2008年5月之前发表的关于运动并发症相关因素的观察性研究以及DA与LD治疗初治患者的随机对照试验(RCT)的文献。对方法学质量进行了严格评估。

结果

选择了12篇关于第一个问题的文章,包括1篇RCT、5篇队列研究、6篇病例对照研究。选择了6篇关于第二个问题的RCT。由于检索到的研究之间存在临床异质性,未进行荟萃分析,定性分析表明初始LD剂量、每千克体重的LD剂量、累积LD剂量和累积LD等效剂量可能是与运动并发症相关的独立因素。从疾病发作到开始使用LD的时间与运动并发症无关。DA作为初始治疗与运动障碍的较晚发生相关(CALM-PD:HR = 0.37,95%CI:0.25 - 0.56,P < 0.001;PELMOPET:HR = 0.48,95%CI = 0.29 - 0.80,P < 0.001;罗匹尼罗056:HR = 0.4,95%CI:0.2 - 0.8,P = 0.007;REAL-PET:HR = 8.28,95%CI:2.46 - 27.93,P < 0.001)。根据现有证据无法得出LD治疗时长与运动并发症之间的关系。

结论

初始LD剂量、每千克体重的LD剂量、累积LD剂量和累积LD等效剂量可能是与运动并发症相关的独立因素。从疾病发作到开始使用LD的时间与运动并发症无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验